MedTrace Logo

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

NCT00211042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2013-04-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the relationship of anti-erythropoietin antibodies to the clinical course and outcome of pure red cell aplasia (PRCA) in participants currently or previously treated with recombinant human erythropoietin.

Conditions

  • Pure Red-cell Aplasia

Interventions

OTHER

No intervention

This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research and Development, L. L. C. Clinical trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2006-12-31

Countries

  • Brazil
  • Canada
  • Germany
  • Norway
  • South Africa
  • Sweden
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00211042 on ClinicalTrials.gov